Eicke Latz to Lymphocyte Antigen 96
This is a "connection" page, showing publications Eicke Latz has written about Lymphocyte Antigen 96.
Connection Strength
0.215
-
Gray P, Michelsen KS, Sirois CM, Lowe E, Shimada K, Crother TR, Chen S, Brikos C, Bulut Y, Latz E, Underhill D, Arditi M. Identification of a novel human MD-2 splice variant that negatively regulates Lipopolysaccharide-induced TLR4 signaling. J Immunol. 2010 Jun 01; 184(11):6359-66.
Score: 0.087
-
Visintin A, Halmen KA, Latz E, Monks BG, Golenbock DT. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol. 2005 Nov 15; 175(10):6465-72.
Score: 0.064
-
Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, Kurt-Jones EA, Golenbock DT, Espevik T. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem. 2002 Dec 06; 277(49):47834-43.
Score: 0.051
-
Visintin A, Latz E, Monks BG, Espevik T, Golenbock DT. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem. 2003 Nov 28; 278(48):48313-20.
Score: 0.014